Oncotelic Therapeutics, Inc. announced that Fatih Uckun, MD, Ph. D, Chief Medical Officer (CMO) of Oncotelic Therapeutics, Inc. (the Company), notified the Company of his resignation as the Company's CMO, effective February 28, 2023. Dr. Seymour Fein MD, Chief Regulatory Officer (CRO) of the Company, will be taking over the CMO role.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.042 USD | +2.94% | +6.60% | +9.66% |
1st Jan change | Capi. | |
---|---|---|
+9.66% | 16.79M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- OTLC Stock
- News Oncotelic Therapeutics, Inc.
- Oncotelic Therapeutics, Inc. Announces Executive Changes